glp 1 in mississippi Pennsylvania Medicaid stopped covering GLP-1s for obesity this year, but it's not all savings Legislative committee weighs cost, benefit

In 2018, Eli Lilly licensed worldwide development and commercialization rights to OWL833 from Chugai in a deal valued at $50 million upfront

In a 12 month RCT in adults with type 2 diabetes comparing intermittent energy restriction (20922510 kJ [500600 kcal] diet for 2 non-consecutive days/week followed by the usual diet for 5 days/week) with continuous energy restriction (50216276 kJ [12001500 kcal] diet for 7 days/week), glycaemic improvements were comparable between the two groups

The game changes, and so must our approach

These signals do not guarantee a product is unsafe, but they do suggest that claims may not be evidence-based

Med Lett Drugs Ther

George , and Cedar City , Utah